Xcout IntelSign inSubscribe

Gubra competitors & alternatives

Biotechnology & CRODenmark

The 12 closest competitors and alternatives to Gubra among biotechnology & cro companies — ranked by similarity to what Gubra actually does, not by market-cap band.

12Competitors listed

Subscribe to see Gubra’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About Gubra

Gubra is a Danish biotech and contract research organization (CRO) specializing in preclinical peptide drug discovery, metabolic research, and advanced imaging services.

Gubra at a glance

Gubra is a biotechnology & cro company headquartered in Denmark. Xcout tracks 15 named people at Gubra, including Markus Rohrwild (Chief Executive Officer (CEO)).

Gubra leadership

  • Markus RohrwildChief Executive Officer (CEO)
  • Kristian BorbosChief Financial Officer (CFO)
  • Grigo GauravChief Technology Officer (CTO)
  • Louise S. DalbøgeChief Science Officer (CSO)
  • Thomas LangenickelChief Medical and Development Officer (CMDO)
  • Monika LesslChair

9 more named people on record for Gubra, with roles, board committees and tenure — see the full roster →

Top 12 Gubra competitors

Ranked by semantic similarity — how close each company is to Gubra by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

VIVA BIOTECH01873 · BiotechShanghai, China
64% matchPublic

Biotech

Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.

Market cap$396.6M
Employees2,169
VIVA BIOTECH competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of Gubra and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for Gubraand every competitor above — in one live dashboard.

Subscribe to Xcout Intel →